Is Broadcom Stock a Millionaire Maker?
Broadcom (Nasdaq: AVGO) stock has gone up more than 64%…
Sell
28
POAI Quote, Financials, Valuation and Earnings
Last price:
$1.01
Seasonality move
:
49.83%
Day range:
$1.00 - $1.10
52-week range:
$0.55 - $3.06
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3.52x
P/B ratio:
4.71x
Volume:
33.9K
Avg. volume:
5.5M
1-year change:
-41.48%
Market cap:
$9.6M
Revenue:
$1.6M
EPS (TTM):
-$3.05
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Predictive Oncology has 180.37% upside to fair value with a price target of -- per share.
POAI vs. S&P 500
-
Over the past 5 trading days, Predictive Oncology has underperformed the S&P 500 by -0.51% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Predictive Oncology does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Predictive Oncology has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Predictive Oncology reported revenues of $345.7K.
Earnings Growth
-
Predictive Oncology has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Predictive Oncology reported earnings per share of -$0.48.
Enterprise value:
8.8M
EV / Invested capital:
--
Price / LTM sales:
3.52x
EV / EBIT:
--
EV / Revenue:
5.33x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.80x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$711.4K
Return On Assets:
-114%
Net Income Margin (TTM):
-921.49%
Return On Equity:
-232.54%
Return On Invested Capital:
-225.62%
Operating Margin:
-669.39%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $1.5M | $1.7M | $1.7M | $319.6K | $611.6K | |
| Gross Profit | $1M | $1.1M | $827.7K | $77.8K | $321K | |
| Operating Income | -$15.3M | -$13M | -$11.9M | -$3M | -$2.1M | |
| EBITDA | -$14M | -$12.1M | -$11M | -$2.5M | -$1.6M | |
| Diluted EPS | -$6.98 | -$3.47 | -$2.44 | -$0.85 | -$0.24 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1.5M | $29.5M | $23.4M | $10.1M | $2.2M | |
| Total Assets | $13.1M | $43.8M | $25.7M | $14.4M | $5M | |
| Current Liabilities | $9.3M | $3.2M | $3.9M | $4M | $3.6M | |
| Total Liabilities | $10.4M | $3.5M | $4M | $6.1M | $5.2M | |
| Total Equity | $2.6M | $40.3M | $21.8M | $8.3M | -$202.6K | |
| Total Debt | $4.4M | -- | -- | $150.4K | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$12.4M | -$11.8M | -$11M | -$2.7M | -$2.1M | |
| Cash From Investing | -$475.7K | -$47.6K | -$9.5K | $15.5K | -- | |
| Cash From Financing | $6.7M | $148.9K | $3.9M | -$111.3K | -$195.8K | |
| Free Cash Flow | -$12.8M | -$11.8M | -$11M | -$2.7M | -$2.1M | |
POAI
Sector
Market Cap
$9.6M
$35.1M
Price % of 52-Week High
34.97%
44.56%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
-40.88%
-40.62%
Beta (5-Year)
1.298
0.662
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$1.08
200-day SMA
Sell
Level
$1.03
Bollinger Bands (100)
Sell
Level
0.93 - 1.49
Chaikin Money Flow
Sell
Level
-602M
20-day SMA
Buy
Level
$1.01
Relative Strength Index (RSI14)
Sell
Level
44.97
ADX Line
Buy
Level
16.07
Williams %R
Neutral
Level
-42.6486
50-day SMA
Sell
Level
$1.17
MACD (12, 26)
Sell
Level
-0.03
25-day Aroon Oscillator
Sell
Level
-56
On Balance Volume
Neutral
Level
752.8M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-57.4281)
Sell
CA Score
(Annual)
Level (-5.8717)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (2)
Sell
Ohlson Score
Level (13.3426)
Sell
Piotroski F Score
(Annual)
Level (3)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Pittsburgh segment that provides services which include the application of AI using its proprietary biobank of 150,000+ tumor samples. It also creates proprietary 3D culture models used in drug development; Birmingham segment that provides contract services and research focused on solubility improvements, stability studies, and protein production; and Eagan segment that produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. It derives maximum revenue from Eagan Segment.
Stock Forecast FAQ
In the current month, POAI has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The POAI average analyst price target in the past 3 months is --.
-
Where Will Predictive Oncology Stock Be In 1 Year?
According to analysts, the consensus estimate is that Predictive Oncology share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Predictive Oncology?
Analysts are divided on their view about Predictive Oncology share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Predictive Oncology is a Sell and believe this share price will drop from its current level to --.
-
What Is Predictive Oncology's Price Target?
The price target for Predictive Oncology over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is POAI A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Predictive Oncology is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of POAI?
You can purchase shares of Predictive Oncology via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Predictive Oncology shares.
-
What Is The Predictive Oncology Share Price Today?
Predictive Oncology was last trading at $1.01 per share. This represents the most recent stock quote for Predictive Oncology. Yesterday, Predictive Oncology closed at $1.03 per share.
-
How To Buy Predictive Oncology Stock Online?
In order to purchase Predictive Oncology stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire The Best Stock to Buy in a Bad Market?
Berkshire Hathaway (NYSE:BRK.A, BRK.B) has historically been one of the…
Is Shopify Stock Still a Buy in 2025 or Has Growth Peaked?
The big picture trends in e‑commerce sales are clearly in…
Stock Ideas
Buy
70
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Buy
60
Is NVDA Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 39x
Alerts
Buy
60
RGC alert for May 7
Regencell Bioscience Holdings [RGC] is up 73.72% over the past day.
Buy
77
FARO alert for May 7
Faro Technologies [FARO] is up 34.66% over the past day.
Buy
63
SKX alert for May 7
Skechers USA [SKX] is down 0.07% over the past day.
